Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Ascorbate Plus Gemcitabine/Carboplatin in MIBC
NCT06493370Phase 2Recruiting
- Sponsor
- University of Kansas Medical Center
- Start
- Jan 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ascorbic acid in Muscle Invasive Bladder Cancer (MIBC), sponsored by University of Kansas Medical Center. Started Jan 2025; status: recruiting.
02
Drugs
ascorbic acid
03
Conditions
Muscle Invasive Bladder Cancer (MIBC)
Beyond the preview
Go deeper on NCT06493370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06493370.